Centro De Ingenieria Genetica Y Biotecnologia

Iraldo Bello Rivero

Ana Aguilera Barreto

Rolando Paez Meireles

Hector Santana Milian

Rolando Páez Meireles

Pedro Lopez Saura

Yanelda Garcia Vega

Lorenzo Anasagasti Angulo

Yeny Torres Ruiz

Elizabeth Blanco Garcés

Giselle Pentón Roll

Pedro López Saura

Pedro LÓPEZ Saura

Héctor Santana Milian

Lorenzo c/o Centro De Ingeniería Genética Y Biotecnología Anasagasti Angulo

The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.

Stabilized pharmaceutical formulations that contain the interferons gammas and alpha in synergistic proportions

A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN &#x3b3;) receptor. In vitro this protein has a T cell growth stimulating activity, it inhibits the growth stimulating activity of IL-2 in T cells, it inhibits the induction of HLA-DR by IFN &#x3b3; and it inhibits the antiproliferative activity of &#x3b3; IFN. This invention can be applied in the field of medicine for the treatment of several pathologies such as autoimmune diseases, graft rejections, chronic inflammations, sepsis, ischemia and reperfusion syndrome and atherosclerosis.

Chimeric antagonist anth1

Growing community of inventors

Cuidad de la Habana, Cuba

Iraldo Bello Rivero